Cancer is a leading cause of death worldwide. According to GLOBOCAN 2012, the incidence of cancer is expected to increase from 14 Million in 2012 to approximately 21 Million by 2030.
The report also covers the global as well as regional prevalence of major types of cancer for which T-cell immunotherapy is used. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level.
The report also provides detailed pipeline analysis of T-cell immunotherapy. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the T-cell immunotherapy market, such as phases, geographies, vectors used, therapeutic indications, technology types, and key players. The segment also covers the list of the key ongoing clinical trials along with their clinical phases. According to the research, CAR-T is the most widely used technology by the companies. Moreover, the report also suggests that most of the T-cell immunotherapies are in the research or pre-clinical phase. Limited number of therapies has been able to cross Phase I of the clinical trials.
Several companies and academic institutions are operating in this market with a focus on developing T-cell immunotherapy for difficult to treat' cancers. These companies are also receiving various funding, grants, and investment from non-industry participants, and other companies and venture capitalist firms, which are aiding them to develop new products. The report provides details about major venture capitalist investments, government grants, and IPO raised in this market.
Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global T-cell Immunotherapy market. The profiles of these companies include business overview, financials, product pipeline, and their strength and weakness analysis.
Key Topics Covered:
1. Analyst View
2. Research Methodology
4. Market Dynamics
5. Major Therapeutic Areas for T-Cell Therapies
6. Pipeline Analysis
7. Investments in T-Cell Immunotherapy
8. Key Player Analysis
- Adaptimmune Therapeutics plc
- Atara Biotherapeutics, Inc.
- Celgene Corporation
- Cell Medica
- Cellular Biomedicine Group
- GlaxoSmithKline plc.
- Gradalis, Inc.
- Immunocore Ltd.
- Immunovative Therapies, Ltd.
- Inovio Pharmaceuticals, Inc.
- Juno Therapeutics, Inc.
- Kite Pharma, Inc.
- Lion Biotechnologies, Inc.
- Novartis International AG
- Tessa Therapeutics Pte Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/dkpd6r/tcell
Related Topics: Oncology Drugs
T-cell Immunotherapy: Clinical Trial Tracker
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/world-t-cell-immunotherapy-for-cancer-pipeline-analysis-2016---research-and-markets-300315330.html
SOURCE Research and Markets